Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19
Taking recent publications into account, one should consider avoiding routine use of hydroxychloroquine, especially if combined with azithromycin, for COVID-19. Such treatment may be associated with the increased risk for hospital mortality and QT prolongation, while there is no documented effective...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Izdatelstvo OKI
2020-10-01
|
| Series: | Качественная клиническая практика |
| Subjects: | |
| Online Access: | https://www.clinvest.ru/jour/article/view/527 |
| _version_ | 1797262026908631040 |
|---|---|
| author | V. A. Otdelenov Yu. Yu. Kiselev K. B. Mirzaev A. V. Matveev D. A. Sychev |
| author_facet | V. A. Otdelenov Yu. Yu. Kiselev K. B. Mirzaev A. V. Matveev D. A. Sychev |
| author_sort | V. A. Otdelenov |
| collection | DOAJ |
| description | Taking recent publications into account, one should consider avoiding routine use of hydroxychloroquine, especially if combined with azithromycin, for COVID-19. Such treatment may be associated with the increased risk for hospital mortality and QT prolongation, while there is no documented effectiveness regarding SARS-CoV-2 clearance and outcomes. This treatment may be considered in individual cases, provided potential benefit and risks are carefully weighted, and safety monitoring is enhanced. Hydroxychloroquine safety in outpatients with COVID-19 is poorly studied and risks are increased by challenges in monitoring QT and electrolytes, hence hydroxychloroquine cannot be considered as first line treatment in outpatient settings. Such use of hydroxychloroquine is not recommended if clinical, instrumental, and laboratory monitoring are not in place. |
| first_indexed | 2024-04-24T23:50:34Z |
| format | Article |
| id | doaj.art-277ef40b470e486eb66c951af4df2b9b |
| institution | Directory Open Access Journal |
| issn | 2588-0519 2618-8473 |
| language | Russian |
| last_indexed | 2024-04-24T23:50:34Z |
| publishDate | 2020-10-01 |
| publisher | Izdatelstvo OKI |
| record_format | Article |
| series | Качественная клиническая практика |
| spelling | doaj.art-277ef40b470e486eb66c951af4df2b9b2024-03-14T18:09:09ZrusIzdatelstvo OKIКачественная клиническая практика2588-05192618-84732020-10-0104S535910.37489/2588-0519-2020-S4-53-59511Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19V. A. Otdelenov0Yu. Yu. Kiselev1K. B. Mirzaev2A. V. Matveev3D. A. Sychev4ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииУниверситет Осло МетрополитенФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииTaking recent publications into account, one should consider avoiding routine use of hydroxychloroquine, especially if combined with azithromycin, for COVID-19. Such treatment may be associated with the increased risk for hospital mortality and QT prolongation, while there is no documented effectiveness regarding SARS-CoV-2 clearance and outcomes. This treatment may be considered in individual cases, provided potential benefit and risks are carefully weighted, and safety monitoring is enhanced. Hydroxychloroquine safety in outpatients with COVID-19 is poorly studied and risks are increased by challenges in monitoring QT and electrolytes, hence hydroxychloroquine cannot be considered as first line treatment in outpatient settings. Such use of hydroxychloroquine is not recommended if clinical, instrumental, and laboratory monitoring are not in place.https://www.clinvest.ru/jour/article/view/527коронавирусмонотерапия гидроксихлорохиномгидроксихлорохин с азитромициномcovid-19 |
| spellingShingle | V. A. Otdelenov Yu. Yu. Kiselev K. B. Mirzaev A. V. Matveev D. A. Sychev Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 Качественная клиническая практика коронавирус монотерапия гидроксихлорохином гидроксихлорохин с азитромицином covid-19 |
| title | Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 |
| title_full | Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 |
| title_fullStr | Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 |
| title_full_unstemmed | Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 |
| title_short | Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 |
| title_sort | adjusting the role of hydroxychloroquine with or without azithromycin in patients with covid 19 |
| topic | коронавирус монотерапия гидроксихлорохином гидроксихлорохин с азитромицином covid-19 |
| url | https://www.clinvest.ru/jour/article/view/527 |
| work_keys_str_mv | AT vaotdelenov adjustingtheroleofhydroxychloroquinewithorwithoutazithromycininpatientswithcovid19 AT yuyukiselev adjustingtheroleofhydroxychloroquinewithorwithoutazithromycininpatientswithcovid19 AT kbmirzaev adjustingtheroleofhydroxychloroquinewithorwithoutazithromycininpatientswithcovid19 AT avmatveev adjustingtheroleofhydroxychloroquinewithorwithoutazithromycininpatientswithcovid19 AT dasychev adjustingtheroleofhydroxychloroquinewithorwithoutazithromycininpatientswithcovid19 |